Poseida Therapeutics Inc.

Poseida Therapeutics, now integrated into the Roche Group following its 2025 acquisition, is a clinical‑stage biopharmaceutical company dedicated to developing curative allogeneic cell therapies and genetic medicines. Leveraging a suite of proprietary platforms—including a non‑viral DNA delivery system, the Cas‑CLOVER™ site‑specific gene‑editing technology, a proprietary booster molecule, and nanoparticle‑based gene delivery—Poseida designs and manufactures GMP‑grade cell therapy products in‑house.

The company’s pipeline targets high‑impact oncology indications such as multiple myeloma and prostate cancer, as well as broader immuno‑oncology and regenerative medicine applications. By combining advanced genome engineering with scalable, off‑the‑shelf cell therapy manufacturing, Poseida offers differentiated, potentially curative solutions that address unmet medical needs and create compelling opportunities for talent in biotech innovation.